Lymphocytic Leukemia

Oncology·MeSH: Leukemia

Prevalence

20.0 / 100K

Incidence

4.7 / 100K/yr

103 drugs in development·40 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(36)
DrugCompany
AcalabrutinibMerus N.V. (MRUS)
AcalabrutinibMerck & Co., Inc. (MRK)
AcalabrutinibAbbVie Inc. (ABBV)
alxn2075ALEXION PHARMACEUTICALS, INC. (ALXN)
apg-2575CHINA PHARMA HOLDINGS, INC. (CPHI)
bendamustineLOXO ONCOLOGY, INC. (LOXO)
bendamustineBeOne Medicines Ltd. (ONC)
bendamustineBeOne Medicines Ltd. (ONC)
BendamustineENANTA PHARMACEUTICALS INC (ENTA)
BendamustineBeOne Medicines Ltd. (ONC)
BGB-16673ENANTA PHARMACEUTICALS INC (ENTA)
BGB-16673BeOne Medicines Ltd. (ONC)
BGB-16673Merus N.V. (MRUS)
epcoritamabGenmab A/S (GMAB)
gamunex-cGrifols S.A. (GRFS)
IbrutinibMerck & Co., Inc. (MRK)
IbrutinibAbbVie Inc. (ABBV)
IdelalisibENANTA PHARMACEUTICALS INC (ENTA)
IdelalisibMerus N.V. (MRUS)
liso-celCELGENE CORP /DE/ (CELG)
NemtabrutinibMerus N.V. (MRUS)
NX-5948Nurix Therapeutics, Inc. (NRIX)
obinutuzumabBeOne Medicines Ltd. (ONC)
ObinutuzumabAbbVie Inc. (ABBV)
ObinutuzumabASTRAZENECA PLC (AZN)
PirtobrutinibBeOne Medicines Ltd. (ONC)
RoginolisibENANTA PHARMACEUTICALS INC (ENTA)
sonrotoclaxBeOne Medicines Ltd. (ONC)
SonrotoclaxBeOne Medicines Ltd. (ONC)
SonrotoclaxENANTA PHARMACEUTICALS INC (ENTA)
SonrotoclaxFilana Therapeutics Inc. (FLNA)
UblituximabASTRAZENECA PLC (AZN)
VenetoclaxASTRAZENECA PLC (AZN)
VenetoclaxBeOne Medicines Ltd. (ONC)
ZanubrutinibFilana Therapeutics Inc. (FLNA)
zilovertamabOncternal Therapeutics, Inc. (ONCT)
Phase 1(26)
DrugCompany
ABT-263AbbVie Inc. (ABBV)
apg-2575ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
apg2575ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
bendamustineAbbVie Inc. (ABBV)
BP1002BIO-PATH HOLDINGS, INC. (BPTH)
duvelisibAbbVie Inc. (ABBV)
EpcoritamabENANTA PHARMACEUTICALS INC (ENTA)
EpcoritamabFilana Therapeutics Inc. (FLNA)
EpcoritamabELI LILLY & Co (LLY)
FCRAbbVie Inc. (ABBV)
FludarabinePRECIGEN, INC. (PGEN)
High dose IL-2IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IL-2IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOV-2001IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IPI-145Filana Therapeutics Inc. (FLNA)
JCAR017 + ibrutinibMerus N.V. (MRUS)
KT-253Kymera Therapeutics, Inc. (KYMR)
kur-502Athenex, Inc. (ATNX)
Low dose IL-2IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
mb-106MUSTANG BIO, INC. (MBIO)
NeoVaxBioNTech SE (BNTX)
NX-2127Nurix Therapeutics, Inc. (NRIX)
NX-5948Keros Therapeutics, Inc. (KROS)
OlaparibRepare Therapeutics Inc. (RPTX)
parsaclisibIncyte Corp. (INCY)
PRGN-3007PRECIGEN, INC. (PGEN)

Compare drugs

belrapzo vs clonoSEQbelrapzo vs Jaypircabelrapzo vs venetoclax

Frequently asked questions

How many drugs are in development for Lymphocytic Leukemia?

BioSniper tracks 103 drugs in development for Lymphocytic Leukemia across 40 companies.

How many clinical trials target Lymphocytic Leukemia?

There are 1 clinical trial targeting Lymphocytic Leukemia tracked by BioSniper.

What is the prevalence of Lymphocytic Leukemia?

The estimated prevalence of Lymphocytic Leukemia is approximately 20.0 per 100,000 population.

Deep-dive into Lymphocytic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis